July 9th, 2015 Sale of Cenexi to Cathay Capital.
Natixis Partners advised the shareholders of Cenexi

Chequers Capital (the reference shareholder of Cenexi Group since 2008) has agreed to sell its shareholding to Cathay Capital, a private equity group specialized in investing in Chinese, European and North-American companies. Cathay Capital was impressed by the management’s project, led by Philippe Mougin, and its ability to integrate and master high added-value technologies.

With sales of €120M, Cenexi is one of the European leaders in the pharmaceutical outsourcing sector. The group helps its clients in their drug development, manufacturing and packaging  activities, with a specific expertise in strong added-value galenic forms.

Cenexi has a workforce of 900 people, operates 3 facilities (2 in France and 1 in Belgium) benefiting from standard international accreditations (including FDA), and generates more than 75% of its revenue abroad (in more than 150 countries).

Cenexi plans to speed up its international development, especially in the USA, with the ambition to become the main partner of pharmaceutical laboratories, more particularly in strong added-value galenic forms.

‹ Back to news

M&A team:

françois rivalland
managing partner

joseph el khoury
executive director

david feiner

Debt Advisory Team:

philippe charbonnier
managing director